Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Pfizer response to questions on M&A -> add value to company

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Oct 21, 2022 1:31pm

102 Views

Post# 35039449

RE:RE:RE:RE:RE:RE:RE:RE:Pfizer response to questions on M&A -> add value to company

As of June 30, 2022 Pfizer reported a revenue increase of $20.0 billion, or 60%, in the first six months of 2022 to $53.4 billion from $33.4 billion in the first six months of 2021, reflecting an operational increase of $22.0 billion, or 66% from the same time last year.

Pfiser has plenty enough cash on hand for an ONCY acquisition.

<< Previous

Bullboard Posts

Next >>

FLYHT and WestJet partner on weather forecasting